rapamune การใช้

• The new stent is coated with Rapamune, usually used to prevent organ rejection in kidney transplants.
• In the new research, patients given Rapamune were weaned off cyclosporine without increasing their risk of kidney rejection.
• While Rapamune has its own side effects, kidney damage doesn't appear to be one of them.
• Rapamycin, also known as Rapamune, is traditionally used as an immunosuppressant to prevent rejection in kidney transplant patients.
• Hricik noted that Rapamune is being used experimentally in recipients of other organs to reduce rejection and cyclosporine-linked kidney damage.
• Rapamune, like cyclosporine, inhibits the function of white blood cells that recognize the donated organ as foreign and attack it.
• Jensik noted that Rapamune can cause significant anemia and, because generic versions aren't available, is more expensive than cyclosporine.
• "The transplant community is very excited " to use drugs like Rapamune to improve long-term outcome, Langnas said.
• American Home Products is set to introduce Rapamune for organ-transplant rejection, a use that should generate some $ 750 million in sales.
• Rapamune is taken along with cyclosporin, another immunosuppressant, and corticosteroids, which reduce inflammation and also suppress the immune system, the FDA added.
• Rapamune won approval Wednesday from the Food and Drug Administration as an addition to the drugs used to suppress the immune system in order to prevent rejection.
• Rapamune, a liquid taken daily, can cost patients $ 3, 000 or more a year, comparable to non-generic versions of cyclosporine pills.
• In 2013, Guttman was lead counsel in an intervened case by the United States Department of Justice against Pfizer Pharmaceutical involving the kidney-transplant drug Rapamune.
• A " whistleblower suit " was filed in 2005 against Wyeth, which was acquired by Pfizer in 2009, alleging that the company illegally marketed their drug Rapamune.
• The drug sirolimus, sold as Rapamune, was approved by the U . S . Food and Drug Administration in 1999 for use in kidney transplant recipients along with cyclosporine.
• Next year, American Home Products plans to introduce Protonix, a gastrointestinal drug available in oral and intravenous forms, and Rapamune, an immuno-suppressive therapy for organ transplants.
• The study, funded by Rapamune maker Wyeth-Ayerst Laboratories, involved 197 kidney transplant patients, about half of whom were weaned off cyclosporine within three months of their operations.
• The drug, known as rapamycin or Rapamune, is marketed by Wyeth-Ayerst Laboratories, a division of American Home Products, to prevent kidney transplant rejection by preventing cell growth.
• On July 30, 2013, The U . S . Department of Justice announced that Pfizer had agreed to pay $ 491 million to settle criminal and civil charges stemming from the pharmaceutical company's illegal marketing of Rapamune.
• It is produced by the ability to inhibit mTOR . It was approved by the US Food and Drug Administration in September 1999 and is marketed under the trade name "'Rapamune "'by Pfizer ( formerly by Wyeth ).